Drug Trial Radar · NCT04643418
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Mar 8, 2022
Primary completion
Mar 31, 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- MegaPro Biomedical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.
Conditions
- Solid Tumor, Unspecified, Adult
Interventions
MPB-1734Drug
Administered once daily in a 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation the the maximum tolerated dose(MTD) by safety dataTime frame: Through the end of the first cycle (Days 1-21).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.